Gland Pharma Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/yqv3sqghdcunf2bdgdbqp9s6.pdf

Key Takeaways


US Business: Syringe Shortages and the Launch Bridge

Srinivas Sadu: “I have not seen a case where the price have gone up in recent times, it always in spite of the shortages, still the prices are kind of normal, but at least it will not go down for sure, but the volumes are increasing for certain products, which we never thought it will increase because of the shortages.”

Enoxaparin: Partner Transition and Margin Ambition


Margins: The 35–37% Floor Under Pressure

Srinivas Sadu: “Internally, like I said, gross margin is not a criteria for us, but at the EBITDA margin level, we always look at 35%-37% levels of EBITDA margins and at the PAT level around 25%. That is how we internally always look towards that.”

India and ROW: The Growth Engines That Delivered

Srinivas Sadu: “There was debate always on this, but I think we want to keep the quality standard across the sites similar, we don't want to dilute that because at a long run that helps because from the corporate quality perspective, we want to have a common quality systems across sites, so there is no confusion and different qualities at different sites.”

Complex Pipeline and Capacity Build-Out


Capital Allocation: M&A and the Biosimilar Pivot

Srinivas Sadu: “Last year is more like the valuations were all over the place. Now, there is some sanity around the valuation. So, we are working actively on couple of things. So, hopefully we should give something in next few months.”

Guidance & Commitments

CommitmentSpecificsTimeline
Syringe shortage resolutionCatch up on backlog; still short 0.3–0.4 crore syringes this quarterNext quarter (Q1/Q2 FY23)
Enoxaparin partner volume shiftPartner volumes expected to entirely shift to GlandJune–July 2022
US launch cadence~24–25 molecules worth ~$3 bn innovator salesNext 3 quarters
CAPEX spend₹300 croresFY23
CAPEX spend₹250 croresFY24
R&D spend ratio4–5% of revenue as complex injectables share risesOngoing
M&A announcementActively working on a couple of things; valuations now saner“Next few months”
Vaccine facility repurposingOne line converting to biosimilars; preliminary work starting soonDiscussions underway, visits done
Internal margin target35–37% EBITDA, ~25% PATOngoing internal benchmark
Company-level growth targetAt least 10%, with 10–11% from new productsFY23

Key Metrics

MetricQ4 FY22
Revenue₹1,103 crore, +24% YoY
Full-year FY22 revenue₹4,400.7 crore, +27% YoY
PAT₹285.9 crore, +10% YoY
Full-year FY22 PAT₹1,211.7 crore, +22% YoY
PAT margin24%, vs 26% for full year FY22
EBITDA₹413.6 crore, +10% YoY
EBITDA margin35%, vs 40% in Q4 FY21
Full-year FY22 EBITDA margin37%, vs 40% in FY21
Core markets revenue share64% of Q4 revenue, vs 74% in Q4 FY21; +8% YoY
Rest of World markets revenue share17% of Q4 revenue, +32% YoY
India market revenue share18% of Q4 revenue, +137% YoY
R&D revenue expense₹44.3 crore, 4% of revenue, vs ₹30.2 crore in Q4 FY21
Full-year FY22 R&D revenue expense₹193.2 crore, +61% YoY; 4.4% of revenue excluding capex R&D
Cash flow from operations (FY22)₹790.8 crore
CAPEX incurred (FY22)₹522.1 crore
Cash conversion cycle (FY22)187 days, improved from 192 days in FY21
ROCE on ex-cash basis33% as on March 31, 2022
ANDA filings in the US (cumulative)311 as on March 31, 2022
Product registrations globally (cumulative)1,557 as on March 31, 2022
Internal API share of revenue33–34%, up from 23–24% a year ago
Profit share contribution~10% of revenue
Effective tax rate~25%
CAPEX plan for FY23₹300 crore